Larimar Therapeutics develops treatments for rare diseases, starting with a drug candidate for Friedreich's ataxia that uses its cell penetrating peptide platform. LRMR reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 14 | Leerink Partners | Assumed coverage | Buy | |
| Jul 2 | HC Wainwright & Co. | Assumed coverage | Buy | |
| Jun 30 | Baird | Maintained | Buy | |
| May 27 | JP Morgan | Initiated | Buy |
Seasonality
How LRMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in LRMR in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LRMR is in one of them and how their past LRMR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LRMR in an article yet. Here's the latest on the wider market.
About Larimar Therapeutics
Larimar Therapeutics is a biotechnology company based in Bala Cynwyd, Pennsylvania, that develops treatments for complex rare diseases. Its lead candidate, nomlabofusp, is a drug given by injection under the skin that is designed to deliver frataxin, a protein the body needs, to patients with Friedreich's ataxia. The company uses its cell penetrating peptide platform, which helps therapeutic molecules cross cell membranes, and it aims to apply that platform to other rare diseases. The drug is still in clinical development and is not yet approved for sale.
- Headquarters
- Bala Cynwyd, PA
- Founded
- 2005
- Website
- zafgen.com ↗